Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy

Accept / Decline

Press releases

Ferring launches New International Fertility Media Award (FIMA) 2010

Recognising the importance of and excellence in reporting of infertility issues and treatment

Amsterdam, The Netherlands, 30 June 2009 - Ferring is proud to announce the launch of its first Fertility Media Award (FIMA) today during the 25th Annual Society of Human Reproduction and Embryology (ESHRE) congress. This new award has been created to honour excellence in the reporting of fertility treatment amongst both consumer and medical media.

There are two entry categories:

  • Best written article on infertility (print / web)
  • Best broadcast report on infertility (radio / TV / film)

Submission for entries opens on 1st July 2009 and closes on 1st March 2010.

The judging panel, chaired by international fertility specialist Professor Paul Devroey (Free University Brussels), will include a fertility patient group representative, a health reporter, Professor Julian Jenkins Ferring's Director Medical Sciences and Ferring's Director of Corporate Communications, Helen Gallagher. 

Helen Gallagher commented; "We are delighted to announce the launch of the FIMA. The award is designed to honour media excellence, reflecting the importance of media coverage in helping infertile couples understand infertility and the treatment options available".

The prize for the winning journalist will be an all paid trip to and entry to ESHRE 2010 under the sponsorship of Ferring for winners of the two categories.

The judging criteria have been pre-set and entries will be assessed against the following:

  • Excellence in fertility writing
  • Demonstration of clear knowledge of infertility treatment and issues
  • Perceived value of article to target audience (educational, impactful)
  • Topicality of subject matter

Entry forms will be distributed to key international journalists and will also be available on request from FIMA@greenhouse-communications.com

- ENDS -

Notes to Editors:

Infertility is generally defined as the inability to conceive naturally after one year of trying to become pregnant by unprotected intercourse. Infertility does not mean sterility, but it does signify a reduction in the chances of conceiving a child spontaneously.  According to the World Health Organisation (WHO), between 60 and 80 million couples in the world are infertile[1], and one in six couples have to seek help to conceive[2]. The problem is found to lie with the male in nearly half of cases, although many attribute the rise of infertility to women opting to postpone motherhood until later in life, which often results in age-related infertility.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology. Ferring's fertility portfolio of treatments gives infertile couples the chance to have babies and includes its flagship brand MENOPUR®, a recognised high quality treatment for infertility. Ferring has operating subsidiaries in over 45 countries. To learn more about Ferring or our products please visit www.ferring.com.

For further information please contact:
Louisa Revill / Claire Pay, Greenhouse Communications
Tel: 44 (0)207 798 9922 / 44 (0)207 798 9900
E-mail: Louisa.Revill@greenhouse-communications.com



[1] http://www.who.int/en/
[2] Hull, MG et al. Population study of causes, treatment, and outcome of infertility. British Medical Journal. 1985 Dec 14;291(6510):1693-7

See more Press releases



TEL:  +41 58 301 00 00
FAX: +41 58 301 00 10


Global Locator